{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T13:34:11Z","timestamp":1769866451493,"version":"3.49.0"},"reference-count":27,"publisher":"Elsevier BV","issue":"1-3","license":[{"start":{"date-parts":[[1991,2,1]],"date-time":"1991-02-01T00:00:00Z","timestamp":665366400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["International Journal of Pharmaceutics"],"published-print":{"date-parts":[[1991,2]]},"DOI":"10.1016\/0378-5173(91)90133-9","type":"journal-article","created":{"date-parts":[[2002,12,14]],"date-time":"2002-12-14T12:11:45Z","timestamp":1039867905000},"page":"111-119","source":"Crossref","is-referenced-by-count":22,"title":["Nanoparticles of polyisohexylcyanoaerylate (PIHCA) as carriers of primaquine: formulation, physico-chemical characterization and acute toxicity"],"prefix":"10.1016","volume":"68","author":[{"given":"R.","family":"Gaspar","sequence":"first","affiliation":[]},{"given":"V.","family":"Pr\u00e9at","sequence":"additional","affiliation":[]},{"given":"M.","family":"Roland","sequence":"additional","affiliation":[]}],"member":"78","reference":[{"key":"10.1016\/0378-5173(91)90133-9_bib1","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/0024-3205(78)90270-9","article-title":"Improved therapy of experimental leishmaniasis by use of a liposome-encapsulated antimonial drug","volume":"22","author":"Alving","year":"1978","journal-title":"Life Sci."},{"key":"10.1016\/0378-5173(91)90133-9_bib2","series-title":"Targeting of Drugs","first-page":"337","article-title":"Therapeutic potential of liposomes as carriers in leishmaniasis, malaria and vaccines","author":"Alving","year":"1982"},{"key":"10.1016\/0378-5173(91)90133-9_bib3","series-title":"Liposome Technology","first-page":"55","article-title":"Preparation of liposomes for use as drug carriers in the treatment of leishmaniasis","author":"Alving","year":"1984"},{"key":"10.1016\/0378-5173(91)90133-9_bib4","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1111\/j.2042-7158.1986.tb04623.x","article-title":"Non-ionic surfactant vesicles, niosomes, as a delivery system for the anti-leishmanial drug sodium stibogluconate","volume":"38","author":"Baillie","year":"1986","journal-title":"J. Pharm. Phamacol."},{"key":"10.1016\/0378-5173(91)90133-9_bib5","series-title":"Leishmaniasis","first-page":"111","article-title":"Experimental chemotherapy of leishmaniasis \u2014 a critical review","author":"Berman","year":"1985"},{"key":"10.1016\/0378-5173(91)90133-9_bib6","doi-asserted-by":"crossref","first-page":"297","DOI":"10.4269\/ajtmh.1986.35.297","article-title":"Activity of pentamidine-containing human red cell ghosts against visceral leishmaniasis in the hamster","volume":"35","author":"Berman","year":"1986","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"10.1016\/0378-5173(91)90133-9_bib7","doi-asserted-by":"crossref","first-page":"753","DOI":"10.4269\/ajtmh.1983.32.753","article-title":"Activity of 8-aminoquinolines against Leishmania tropica within human macrophages in vitro","volume":"32","author":"Berman","year":"1983","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"10.1016\/0378-5173(91)90133-9_bib8","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/0014-5793(87)80072-8","article-title":"Antimalarial activity and inhibition of monoamine oxidases A and B by exo-erythrocytic antimalarials: optical isomers of primaquine, N-acylated congeners, primaquine metabolites and 5-phenoxy-substituted analogues","volume":"214","author":"Brossi","year":"1987","journal-title":"FEBS Lett."},{"key":"10.1016\/0378-5173(91)90133-9_bib9","first-page":"1","article-title":"Polyalkylcyanoacrylates as colloidal drug carriers","volume":"5","author":"Couvreur","year":"1988","journal-title":"CRC Crit. Rev. Ther. Drug Carrier Syst."},{"key":"10.1016\/0378-5173(91)90133-9_bib10","doi-asserted-by":"crossref","unstructured":"Couvreur P., Roland M. and Speiser P., US Patent 4329332, 1982.","DOI":"10.1002\/jps.2600710717"},{"key":"10.1016\/0378-5173(91)90133-9_bib11","series-title":"Targeting of Drugs with Synthetic Systems","first-page":"123","article-title":"Targeting of colloidal carriers and the role of surface properties","author":"Davis","year":"1986"},{"key":"10.1016\/0378-5173(91)90133-9_bib12","first-page":"109","article-title":"Endocytosis and intracellular drug delivery","volume":"35","author":"Eldem","year":"1989","journal-title":"Acta Pharm. Technol."},{"key":"10.1016\/0378-5173(91)90133-9_bib13","series-title":"Physicochemical Principles of Pharmacy","author":"Florence","year":"1988"},{"key":"10.1016\/0378-5173(91)90133-9_bib14","doi-asserted-by":"crossref","first-page":"29","DOI":"10.3109\/02652048909019899","article-title":"Development of dehydroemetine nanoparticles for the treatment of visceral leishmaniasis","volume":"6","author":"Fouarge","year":"1989","journal-title":"J. Microencaps."},{"key":"10.1016\/0378-5173(91)90133-9_bib15","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/0378-5173(83)90166-7","article-title":"Pharmacokinetics and distribution of a biodegradable drug-carrier","volume":"15","author":"Grislain","year":"1983","journal-title":"Int. J. Pharm."},{"key":"10.1016\/0378-5173(91)90133-9_bib16","series-title":"Host-Parasite Cellular and Molecular Interactions in Protozoal Infections","first-page":"203","article-title":"Leishmania host-parasite interactions: the develop- ment of chemotherapeutic targets and specific drug delivery systems. 1. Lipoprotein-mediated antileishmanial chem- otherapy","author":"Hart","year":"1987"},{"key":"10.1016\/0378-5173(91)90133-9_bib17","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1002\/jps.2600710716","article-title":"Toxicity of polyalkylcyanoacrylate nanoparticles. I: Free nanoparticles","volume":"71","author":"Kante","year":"1982","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/0378-5173(91)90133-9_bib18","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/0142-9612(84)90002-4","article-title":"Degradation of polyisobutylcyanoacrylate nanoparticles","volume":"5","author":"Lenaerts","year":"1984","journal-title":"Biomaterials"},{"key":"10.1016\/0378-5173(91)90133-9_bib19","first-page":"99","article-title":"A simplified method for evaluating dose-effect experiments","volume":"96","author":"Lichtfield","year":"1949","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/0378-5173(91)90133-9_bib20","series-title":"Primaquine: Pharmacokinetics, Metabolism, Toxicity and Activity","first-page":"3","article-title":"Primaquine: studies of mammalian metabolism","author":"McChesney","year":"1987"},{"key":"10.1016\/0378-5173(91)90133-9_bib21","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1038\/272055a0","article-title":"Antileishmanial activity of antimonials entrapped in liposomes","volume":"272","author":"New","year":"1978","journal-title":"Nature"},{"key":"10.1016\/0378-5173(91)90133-9_bib22","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1002\/jps.2600730943","article-title":"High-performance liquid chromatographic-ultraviolet determination of primaquine and its metabolites in human plasma and urine","volume":"73","author":"Parkhurst","year":"1984","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/0378-5173(91)90133-9_bib23","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1080\/00034983.1980.11687347","article-title":"The experimental chemotherapy of leishmaniasis V: the activity of potential leishmanicides against \u2018L.infantum LV9\u2019 in NMRI mice","volume":"74","author":"Peters","year":"1980","journal-title":"Ann. Trop. Med. Parasitol."},{"key":"10.1016\/0378-5173(91)90133-9_bib24","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/0378-5173(87)90171-2","article-title":"Biodegradable microspheres VIII. Killing of Leishmania donovani in cultured macrophages by micro-particle-bound primaquine","volume":"40","author":"Stj\u00e4rnkvist","year":"1987","journal-title":"Int. J. Pharm."},{"key":"10.1016\/0378-5173(91)90133-9_bib25","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1001\/archinte.1962.03620140081013","article-title":"Primaquine sensitivity","volume":"109","author":"Tarlov","year":"1962","journal-title":"Arch. Int. Med."},{"key":"10.1016\/0378-5173(91)90133-9_bib26","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1023\/A:1016366022712","article-title":"Molecular weights of free and drug-loaded nanoparticles","volume":"1","author":"Vansnick","year":"1985","journal-title":"Pharm Res."},{"key":"10.1016\/0378-5173(91)90133-9_bib27","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/0168-3659(86)90081-7","article-title":"Development of a nanoparticle controlled-release formulation for human use","volume":"3","author":"Verdun","year":"1986","journal-title":"J. Controlled Release"}],"container-title":["International Journal of Pharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:0378517391901339?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:0378517391901339?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T10:27:43Z","timestamp":1554114463000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/0378517391901339"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1991,2]]},"references-count":27,"journal-issue":{"issue":"1-3","published-print":{"date-parts":[[1991,2]]}},"alternative-id":["0378517391901339"],"URL":"https:\/\/doi.org\/10.1016\/0378-5173(91)90133-9","relation":{},"ISSN":["0378-5173"],"issn-type":[{"value":"0378-5173","type":"print"}],"subject":[],"published":{"date-parts":[[1991,2]]}}}